AbstractThe Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for selected drugs, with implications for innovation. Using ClinicalTrials.gov data on biopharmaceutical trials initiated during 2015–24, we found that overall trial activity remained stable, returning to prepandemic levels, but manufacturers with drugs subject to negotiation initiated fewer trials, particularly in certain cancers.
